Arcturus Therapeutics (ARCT) AI Stock Analysis

• Market Cap: $373.72M
• Dividend Yield: N/A
• Average Volume (3M): 496.95K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.33
• Revenue Growth: 15.40%
• EPS Growth: 35.42%
• Country: US
• Employees: 174
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): -0.52
• Shares Outstanding: 27,120,604
• 10 Day Avg. Volume: 429,431
• 30 Day Avg. Volume: 496,950
• PEG Ratio: -0.29
• Price to Book (P/B): 1.54
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.05
• Enterprise Value/Market Cap: 0.49
• Enterprise Value/Revenue: 0.32
• Enterprise Value/Gross Profit: 1.34
• Enterprise Value/Ebitda: -0.72
• 1Y Price Target: $48.20
• Price Target Upside: 262.13% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8

• Rating: 53 Neutral
• Price Target: $14.00 ▲(5.18%Upside)

Arcturus Therapeutics' overall stock score reflects significant financial challenges, with declining revenues and persistent losses impacting profitability and cash flow. Despite these issues, technical indicators show moderate bullish momentum, and recent corporate events suggest potential for future growth. However, the negative valuation and financial performance weigh heavily on the score.

Positive Factors

Efficacy Results

Efficacy results across key biomarkers are encouraging, showing statistically significant evidence of changes from baseline in glutamine and ureagenesis.

Safety Profile

ARCT-810 was generally safe and well tolerated with the optimized infusion regimen, a clear positive, particularly given the lack of steroid pre-treatment.

Strategic Positioning

Arcturus' highly purified mRNA gets into the liver cells of patients and generates functional enzymes, which is seen as derisking for the entirety of Arcturus' liver-focused pipeline.

Negative Factors

Competitive Environment

The muted stock response seems likely to reflect the competitive environment for treating urea-cycle disorders where one-and-done approaches, such as gene-therapy and gene-editing, are on the table.

Data Limitations

Definite limitations of the current data set (small N, differing protocols) and uncertainty on the regulatory path.

Trial Variability

The trial’s small N and mixed individual 15N readout introduced questions on ARCT-810’s magnitude of effect.

Arcturus Therapeutics Business Overview & Revenue Model

Company Description

Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.

How the Company Makes Money

Arcturus Therapeutics primarily generates revenue through partnerships and collaborations with other pharmaceutical companies. These partnerships often involve licensing agreements, where Arcturus grants rights to its proprietary technologies and product candidates, in exchange for upfront payments, milestone payments, and potential royalties on sales. Additionally, the company may receive funding from governmental or non-governmental organizations for specific research and development projects. Arcturus' revenue model is heavily reliant on the successful development and commercialization of its RNA-based products, as well as the strategic alliances it forms to leverage its technological innovations.

Arcturus Therapeutics Financial Statement Overview

Summary

Arcturus Therapeutics faces significant financial challenges, with declining revenues and persistent losses impacting profitability and cash flow. While the balance sheet remains relatively stable with low leverage, the negative cash flow trends and profitability issues pose risks to financial stability.

Income Statement

Arcturus Therapeutics has experienced a significant decline in revenue from 2022 to TTM, with a negative revenue growth rate. The gross profit margin is positive, but the net profit margin is negative due to substantial net losses. The EBIT and EBITDA margins are also negative, reflecting ongoing operational challenges.

Balance Sheet

The company's balance sheet shows a relatively low debt-to-equity ratio, indicating manageable leverage. However, the return on equity is negative due to net losses. The equity ratio is strong, suggesting a solid capital structure with a significant portion of assets financed by equity.

Cash Flow

Arcturus Therapeutics has negative free cash flow and operating cash flow, indicating cash burn. The free cash flow growth rate is negative, showing deterioration in cash generation. The ratios of operating and free cash flow to net income are not favorable, highlighting cash flow challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	135.17M	138.39M	157.75M	205.75M	12.36M	9.54M
Gross Profit	136.31M	134.84M	154.79M	62.70M	-159.50M	-46.41M
EBITDA	-60.17M	-77.40M	-24.17M	13.70M	-201.66M	-70.64M
Net Income	-68.20M	-80.94M	-29.73M	9.35M	-206.86M	-71.36M
Balance Sheet
Total Assets	331.79M	344.07M	429.40M	450.39M	392.81M	476.46M
Cash, Cash Equivalents and Short-Term Investments	216.95M	237.03M	292.00M	391.88M	370.49M	462.89M
Total Debt	38.99M	28.55M	30.22M	90.87M	67.61M	17.87M
Total Liabilities	98.03M	103.09M	150.89M	180.07M	164.60M	79.90M
Stockholders Equity	233.76M	240.98M	278.51M	270.31M	228.21M	396.55M
Cash Flow
Free Cash Flow	-89.09M	-60.40M	-21.00M	24.27M	-138.45M	-44.60M
Operating Cash Flow	-89.55M	-59.75M	-18.10M	31.99M	-135.04M	-42.86M
Investing Cash Flow	-545.00K	-648.00K	-2.90M	-7.73M	-3.41M	-1.74M
Financing Cash Flow	18.39M	5.42M	-24.09M	-2.86M	48.02M	436.14M

Arcturus Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 13.31
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARCT, the sentiment is Negative. The current price of 13.31 is below the 20-day moving average (MA) of 13.33, above the 50-day MA of 12.61, and below the 200-day MA of 15.62, indicating a neutral trend. The MACD of 0.38 indicates Negative momentum. The RSI at 50.47 is Neutral, neither overbought nor oversold. The STOCH value of 47.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ARCT.

Arcturus Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ATAI	62 Neutral	$525.97M	―	-62.43%	―	-0.90%	-89.51%
Sector *	57 Neutral	£4.82B	6.64	-62.36%	5.43%	34.03%	6.31%
ARCT	53 Neutral	$373.72M	―	-27.40%	―	15.40%	35.42%
VSTM	44 Neutral	$257.44M	―	-2159.50%	―	―	14.39%
AURA	43 Neutral	$396.83M	―	-56.24%	―	―	9.22%
ORKA	41 Neutral	$532.78M	―	-39.06%	―	―	-48.01%

Arcturus Therapeutics Corporate Events

Arcturus Therapeutics Announces Positive Phase 2 Results

On June 30, 2025, Arcturus Therapeutics announced positive interim results from Phase 2 studies of ARCT-810, an mRNA therapeutic for treating OTC deficiency. The studies showed significant reductions in glutamine levels and improvements in urea cycle function, with ARCT-810 being safe and well tolerated. These findings suggest a promising path forward for addressing an unmet medical need in OTC deficiency, potentially leading to a pivotal study.

The most recent analyst rating on (ARCT) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Arcturus Therapeutics stock, see the ARCT Stock Forecast page.

Arcturus Therapeutics Approves Key Proposals at Annual Meeting

On June 6, 2025, Arcturus Therapeutics held its annual stockholders meeting where key proposals were voted on, including the election of nine directors to the Board, approval of executive compensation, and the ratification of Deloitte as the independent accounting firm for 2025. All proposals were approved, indicating strong shareholder support for the company’s leadership and strategic direction.

The most recent analyst rating on (ARCT) stock is a Buy with a $63.00 price target. To see the full list of analyst forecasts on Arcturus Therapeutics stock, see the ARCT Stock Forecast page.